Clinical trials: Flu
2009 H1N1 Influenza Virus
Effects of Age on Response to the 2009 H1N1 Virus Vaccine
Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older.
- Trial name
- NCT01055184
- Testing
- 2009 H1N1 Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy
Influnza vaccination is highly recommended over the age of 50,but is only 50% efficatious among the elderly. A Vaccine given as a nasal spray may improve compliance and local immunity.Liposomes are lipid particles that may serve…
- Trial name
- NCT00197301
- Testing
- Vaccination
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Influenza, Human
A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers
This is a non-controlled, open-label, single-centre, dose-escalation study to determine the safety, infectivity and immunology of the potential novel influenza virus H3N2 challenge strain.
- Trial name
- NCT04372719
- Testing
- H3N2
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SGS Life Sciences, a division of SGS Belgium NV
Pregnancy, Influenza
Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry
The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine…
- Trial name
- NCT02554409
- Testing
- Quadrivalent Intradermal Influenza Vaccine (QIV)
- Where
- 5 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
T-cell Response-Flu Risk in Older Adults
The purpose of this study is to determine how the immune system changes with aging and makes influenza a more serious illness in older people.
- Trial name
- NCT00138398
- Testing
- Commercial TriValent Split Influenza Virus
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07121192
- Testing
- Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1
- Where
- 22 sites in United States
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV)
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be…
- Trial name
- NCT01709019
- Testing
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
- Where
- 4 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Influenza Vaccination Among the Elderly Individuals
The aims of the study are to a) identify individuals with a poor response to influenza vaccination and b) identify factors associated with a poor response to influenza vaccination.
- Trial name
- NCT02362919
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Helmholtz Centre for Infection Research
Influenza, Human
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of…
- Trial name
- NCT06382311
- Testing
- Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3.
- Where
- 21 sites in United States
- Volunteers
- 991 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
PRIMAGE (Probiotics, Immunity and Ageing)
Ageing dramatically affects immune function; this phenomenon is known as immunosenescence and partly explains the increased susceptibility for infection in older individuals.
- Trial name
- PRIMAGE (NCT01066377)
- Testing
- Prebiotic and probiotic mix
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Reading
Influenza
Eldery High Dose TIV 2005
The purpose of this study is to compare a new higher-dose influenza virus vaccine to the standard dose vaccine in elderly adults who can walk.
- Trial name
- NCT00115531
- Testing
- Trivalent inactivated influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Immunisation
Development of Childhood Anti-Influenza Immunity
This study is a prospective surveillance of the immune response to seasonal vaccination in healthy children. The study will enroll a total of approximately 220 subjects.
- Trial name
- NCT03673345
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03
This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18…
- Trial name
- NCT00731029
- Testing
- Thiomersal free trivalent influenza split vaccine 2002/2003, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
- Where
- Germany
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Synctial Virus Infections
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
- Trial name
- NCT06890429
- Testing
- RSV/Flu-01E
- Where
- 3 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
Bacterial Growth, Novel Influenza A (H1N1)
The Research of Novel Electrolyzed Water Spray to Eradicate Bacteria E-coli and an Attenuated Human Flu Virus
The purpose of this study is to test whether spraying the hand of patients by use of the novel electrolyzed water spray will decrease the number of bacteria E-coli and the virus titer of an attenuated human flu virus.
- Trial name
- NCT05797103
- Testing
- A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dove Medical Press Ltd
Influenza
Study of a Flu Vaccine in Children
This study tests the safety and effectiveness of a flu vaccine in school children. School children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings…
- Trial name
- NCT00001127
- Testing
- Influenza virus vaccine (CAIV-T)
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)
The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.
- Trial name
- NCT01299142
- Testing
- FGI-101-1A6
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Functional Genetics Inc.
Influenza
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic influenza A vaccine (H5N1).
- Trial name
- NCT00900588
- Testing
- split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19, Influenza
Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine
This study is an open-label, single-center, randomized phase IV clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04801888
- Testing
- Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.